Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab    GEN   DK0010272202

GENMAB (GEN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
06/13/2018 06/14/2018 06/15/2018 06/18/2018 06/19/2018 Date
968(c) 987.8(c) 960.4(c) 951.2(c) 960.2 Last
188 426 174 399 366 211 158 759 204 202 Volume
0.00% +2.05% -2.77% -0.96% +0.95% Change
More quotes
Financials (DKK)
Sales 2018 2 948 M
EBIT 2018 1 467 M
Net income 2018 1 365 M
Finance 2018 5 910 M
Yield 2018 0,01%
Sales 2019 4 364 M
EBIT 2019 2 592 M
Net income 2019 2 419 M
Finance 2019 7 941 M
Yield 2019 0,01%
P/E ratio 2018 43,72
P/E ratio 2019 25,35
EV / Sales2018 18,0x
EV / Sales2019 11,7x
Capitalization 59 004 M
More Financials
Company
Genmab A/S operates as an international biotechnology company.The firm develops human antibody therapeutics for the treatment of cancer.Its antibody product, Arzerra used in the treatment of chronic lymphocytic leukemia indications; and DARZALEX.The company was founded by Donald Lee Drakeman,... 
More about the company
Surperformance© ratings of Genmab
Trading Rating : Investor Rating :
More Ratings
Latest news on GENMAB
06/15SEATTLE GENETICS : Announces First Patient Dosed in Phase 2 Trial of Tisotumab V..
AQ
06/14SEATTLE GENETICS : Announces First Patient Dosed in Phase 2 Trial of Tisotumab V..
AQ
06/07GENMAB : Grant of Restricted Stock Units and Warrants to Genmab employees
AQ
05/31JOHNSON & JOHNSON : `s Darzalex ambitions take a hit with scrapped I-O trials
AQ
05/30GENMAB : Patient Deaths Cited as Darzalex Combination Trials Halted
AQ
05/29GENMAB : to Present at the Goldman Sachs 39th Annual Global Healthcare Conferenc..
AQ
05/28GENMAB : #18-901 Recalculation of reference value for certain instruments with G..
AQ
05/25GENMAB : Announces Topline Results in Phase III study of Arzerra in Indolent Non..
AQ
05/25GENMAB : Announces Topline Results in Phase III study of Arzerra in Indolent Non..
AQ
05/25GENMAB : Announces Topline Results in Phase III study of Arzerra in Indolent Non..
AQ
More news
Sector news : Bio Therapeutic Drugs
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
06/06Drugmaker Lundbeck to settle U.S. charity probe for $52.6 million
RE
06/01Lilly, Incyte Get FDA OK for Lower-Dose Rheumatoid Arthritis Drug
DJ
05/30Gap in regulating biotech drug copies prompts WHO to step in
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/12$GEN A/S Genmabs 1Q Darzalex Sales Track Expectations; E.U. 1L Multiple Myel.. 
05/30#Genmab broke neckline of HEAD AND SHOULDER TOP - target 500DKK , be careful..
1
05/29#3 Genmab takes a hit after J&J sounds retreat on cancer combos, as patie..
2
05/29Genmab down 20% on Darzalex setback  
05/29$BINV Genetics Inc MorphoSys AG ImmunoGenes AG Genmab A/S Dyax Corp Ablynx N.. 
More tweets
Qtime:34
News from SeekingAlpha
06/08EC OKs AstraZeneca's Tagrisso for first-line lung cancer 
05/29Genmab down 20% on Darzalex setback 
05/273 THINGS IN BIOTECH, MAY 26 : Immunotherapy Strikes Lung Cancer Yet Again 
05/24Genmab's pain is Verastem's gain, up 5% 
05/24Genmab's ofatumumab flunks late-stage NHL study 
Chart GENMAB
Duration : Period :
Genmab Technical Analysis Chart | GEN | DK0010272202 | 4-Traders
Technical analysis trends GENMAB
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 1 361  DKK
Spread / Average Target 42%
EPS Revisions
Managers
NameTitle
Jan G. J. van de Winkel President & Chief Executive Officer
Mats Gunnar Pettersson Chairman
David Andrew Eatwell Chief Financial Officer & Executive Vice President
Anders Gersel Pedersen Deputy Chairman
Pernille Lyngvold Erenbjerg Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB-6.67%9 197
GILEAD SCIENCES-1.97%91 317
VERTEX PHARMACEUTICALS3.44%39 504
REGENERON PHARMACEUTICALS-16.13%33 406
NEUROCRINE BIOSCIENCES, INC.31.87%9 198
BLUEBIRD BIO INC2.81%9 177